In this single center analysis, we compared matched related donor transplantation (MRD-HSCT) with haplo-HSCT in patients with acute leukemia and MDS. There was no significant differences in OS, PFS, occurrence of GvHD and toxicity in terms of infections comparing MRD-HSCT vs haplo-HSCT besides a slower leucocyte- and platelet-recovery after haplo-HSCT. However, this was not associated with an increased risk for severe infections. Thus, haplo-HSCT appears to be a safe and reasonable alternative not only to MUD-HSCT but also to MRD-HSCT.
«
In this single center analysis, we compared matched related donor transplantation (MRD-HSCT) with haplo-HSCT in patients with acute leukemia and MDS. There was no significant differences in OS, PFS, occurrence of GvHD and toxicity in terms of infections comparing MRD-HSCT vs haplo-HSCT besides a slower leucocyte- and platelet-recovery after haplo-HSCT. However, this was not associated with an increased risk for severe infections. Thus, haplo-HSCT appears to be a safe and reasonable alternative n...
»